anticorps monoclonaux (hors anti-TNF alpha)

Substances dans la classe

védolizumab ustékinumab trastuzumab tocilizumab ramucirumab pembrolizumab panitumumab ofatumumab natalizumab ipilimumab ibritumomab cetuximab canakinumab brentuximab bélimumab